- Previous Close
18.200 - Open
18.480 - Bid 17.800 x --
- Ask 17.800 x --
- Day's Range
17.680 - 18.480 - 52 Week Range
11.180 - 22.800 - Volume
4,117,583 - Avg. Volume
9,142,286 - Market Cap (intraday)
105.631B - Beta (5Y Monthly) 0.65
- PE Ratio (TTM)
21.98 - EPS (TTM)
0.810 - Earnings Date Mar 24, 2025 - Mar 28, 2025
- Forward Dividend & Yield 0.34 (1.91%)
- Ex-Dividend Date Sep 20, 2024
- 1y Target Est
23.35
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-tumor, anti-infection, central nervous system diseases, oncology, metabolic and autoimmune diseases, etc. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Hengmu, Mailingda, Hengsen, XINYUE, Saint Luolai, Fulaimei, Pulaitan, Tanneng, Ameining, Oulanning, Ruibote, Fulaidi, Fulairui, and Puruian tablets. The company serves pharmaceutical product distributors. It has licence agreements with GSK plc to develop, manufacture, and commercialise HS20089 and HS-20093; GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089; and Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product, as well as collaboration agreement with Antengene Corporation Limited to commercialize selinexor and any product containing or comprising Selinexor. In addition, it engages in trading business. The company was founded in 1995 and is headquartered in Shanghai, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
www.hspharm.com9,099
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 3692.HK
View MorePerformance Overview: 3692.HK
Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 3692.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 3692.HK
View MoreValuation Measures
Market Cap
105.63B
Enterprise Value
80.75B
Trailing P/E
22.01
Forward P/E
24.51
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.33
Price/Book (mrq)
3.56
Enterprise Value/Revenue
6.27
Enterprise Value/EBITDA
13.03
Financial Highlights
Profitability and Income Statement
Profit Margin
38.97%
Return on Assets (ttm)
8.33%
Return on Equity (ttm)
18.10%
Revenue (ttm)
12.1B
Net Income Avi to Common (ttm)
4.71B
Diluted EPS (ttm)
0.810
Balance Sheet and Cash Flow
Total Cash (mrq)
23.5B
Total Debt/Equity (mrq)
0.43%
Levered Free Cash Flow (ttm)
3.41B